Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Our specialist services

Adaptive Phase I & II
Adaptive Phase III
TQT Studies
Bridging Studies
Patient Recruitment
Data Management
Gene Editing & Gene Silencing
Regulatory Strategy Services
Pharmacovigilance

サービス一覧

適応的第I相・第II相試験
適応的第III相試験
TQT試験（心電図QT間隔評価試験）
ブリッジング試験
被験者リクルートメント
データマネジメント
遺伝子編集・遺伝子サイレンシング
規制戦略サービス
ファーマコビジランス
YOU ARE HERE: HOME > NEWS

New CRO unit facility welcomes first overnight patients

31
March 2017

Richmond Pharmacology has been busy settling in their first patients at the new London Bridge site.

View Article

Richmond Pharmacology Opens New London Bridge Site

3
March 2017

This decision marks the next step in Richmond Pharmacology’s continued growth, having already conducted over 300 studies in London since 2001, often in rare disease areas such as amyloidosis.

View Article

Accelerated Early Phase Drug Development in the UK and Europe

11
November 2016

Hear the latest updates about how early phase studies can be accelerated globally by starting first in human trials in the UK then rapidly progress into Europe. This will give you access to a population of 500 million people.

View Article

Inotrem successfully completes its first phase I clinical trial with Motrem™, a TREM-1 pathway modulator for the treatment of septic shock

21
September 2016

Paris, France, September 13, 2016

View Article

Futura Medical plc announce headline results from its efficacy study of the Company's novel gel for the treatment of erectile dysfunction

21
September 2016

<p></p>

View Article

Access 500 million patients. Regulators, sponsors....

23
March 2016

Organised by the British Consulate Boston; The Medicines and Healthcare products Regulatory Agency (MHRA), sponsors and investigators came together...

View Article

Meet the experts

Meet the leadership team and scientific experts behind Richmond Pharmacology's clinical research excellence.

Careers at Richmond

We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.

Our Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director

July 13, 2026
Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Dr Daniel Chapple PhD FCIM as Commercial Director.
Read more

Upcoming Event

ESC Congress 2026

28 - 31 August 2026
Richmond Pharmacology is pleased to attend the ESC Congress 2026 in Munich, Germany, on 28 - 31 August 2026.
View event
© 2026 Richmond Pharmacology - all rights reserved
Disclaimer
|
Sitemap
|
Privacy Policy
|
Report A Concern
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
PreferencesRejectAccept